Physician profile
Benjamin D Dijoseph
NPI 1841375565
$9,926.07
in general payments reported to CMS, 2019-2025
22 companies · $496 in 2025
The $496 reported for 2025 was more than what 80% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $223 · 2020: $66.18 · 2021: $16.30 · 2022: $7,016 · 2023: $258 · 2024: $1,851 · 2025: $496.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,315 · Travel and Lodging: $1,290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,315.28 |
| Travel and Lodging | $1,289.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $8,278.76 | 2022-2024 | Da Vinci Surgical System |
| Astellas Pharma US INC | $241.11 | 2023-2025 | Veozah |
| Hologic Sales and Service, LLC | $208.04 | 2019-2025 | Fluent Fluid Management System, Thinprep 2000 Processor |
| Davol INC. | $206.75 | 2022-2025 | Arista, Arista Ah Flexitip |
| Abbvie INC. | $204.64 | 2019-2025 | Liletta, Lo Loestrin Fe |
| Sumitomo Pharma America, INC. | $161.85 | 2023-2025 | Myfembree |
| Sage Therapeutics, LLC | $120.93 | 2024-2025 | Zurzuvae |
| Organon LLC | $86.95 | 2023-2025 | Nexplanon, Jada System |
| Daiichi Sankyo INC. | $69.68 | 2022-2023 | Injectafer |
| Mimedx Group, INC. | $43.90 | 2025 | |
| Exeltis, USA INC. | $43.55 | 2020-2023 | Slynd |
| Avion Pharmaceuticals | $41.74 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $40.46 | 2023-2024 | |
| Medtronic, INC. | $35.90 | 2021-2024 | Truclear |
| Pfizer INC. | $30.91 | 2023-2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $28.47 | 2019 | |
| Supernus Pharmaceuticals, INC. | $16.46 | 2025 | Qelbree |
| Therapeuticsmd, INC. | $14.84 | 2019 | |
| Amag Pharmaceuticals, INC. | $13.62 | 2019 | |
| Agile Therapeutics, INC. | $13.48 | 2022 | |
| Millicent US INC | $12.38 | 2020 | |
| Pacira Pharmaceuticals Incorporated | $11.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Dijoseph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.